We are paving the way for high-throughput psychometrics.
We observe performance and behaviors in virtual world setups instead of relying on self-reports.
Our approach aims at psychological concepts that were previously beyond the methodological means of psychometrics.
Our methods set new standards in test economic efficiency.
Alejandro Antalich Co-founder, Chairman of the Board
Mr. Antalich is the former Chief Executive Officer of the Canadian Company ICC Labs Inc. (TSXV), the first publicly traded company in the world to sell cannabis to a federal government, bridging the gap between the stigma behind certain controlled substances and regulators. Through strategic foresight, determination, commitment, responsibility, teamwork and passion, he led ICC Labs to its successful sale to Aurora (TSX) in November 2018, one of the largest participants in the industry, a $300 million transaction. An entrepreneur and investor with a commercial instinct and vision towards business growth, with expertise in public markets, mergers and acquisitions, corporate strategy, medtech and foodtech sectors, pharmaceutical industry, operations, manufacturing and product development. A savvy negotiator that manages unique relationship building skills. Focused on innovation, biotechnology, biomedical sciences and clinical research, he also leads Biomind Labs Inc., a Canadian publicly traded life sciences company specialized in fast acting psychedelics and tailored drug delivery systems targeting specific therapeutic indications. He sits on the boards of several companies.
Simon Vumbaca Board Member
Mr. Vumbaca has over 20 years of experience as a strategic advisor to senior leaders and influencers and has worked in the background globally throughout the corporate, financial and governmental worlds. He is deeply passionate about having a holistic birds-eye approach to every unique situation, considering all the angles. Simon's broad spectrum of clients includes Formula 1 racing tracks, Moto GP riders, athletes, pharmaceuticals, footballers, agents, high profile individuals and government officials. An expert in corporate strategy, public sector strategy, mergers & acquisitions, organizational strategy and functional strategy, with focus on turbo-boosting answers to the challenges companies face to ensure a successful outcome. He sits on the boards of several companies and can be available as a non-executive director. He works in English, Spanish, French, and Italian primarily.
Tuula Palmén Board Member
Mrs. Palmén has 20 years of experience in Finnish innovation and industrial policy. She has participated in planning and execution of national and regional strategies focusing on life science, biotech, pharma, food, digital health, medtech and sustainability. She led the development of Finnish synthetic biology ecosystem and its integration to global ecosystems in 2018-2022, and Health Capital Helsinki to create the basis for the Helsinki Metropolitan region to become one of the leading health hubs in Nordics and Europe in 2015-2018. She was responsible for the development of the life science field in Oulu 2006-2015 and in Helsinki 2003-2006. She received her Ph.D from the University of Helsinki in 2003. She also is eMBA from Hanken School of Economics & SSE in 2020. Further, Mrs. Palmén has over 10 years of experience in international business in sales and marketing, in medical device, diagnostic and biotech industry at KONE Corporation, Tamro Corporation and Immuno Diagnostics.
